Indivumed Group
Multi-Omics Solution Provider for Precision Oncology

With technological advance¬ments, conventional cancer treatments like radiation and chemotherapy are fall¬ing behind, and people are seeking personal¬ized cancer treatment options that provide a higher chance of recovery. Furthermore, rising awareness regarding cancer treatment is expected to impel the demand for related medicines. The surge in need for oncological R&D and escalating concerns over increased death rates are further driving the market share for drugs. Introduction to new drugs for cancer by leading biopharmaceutical gi¬ants is also likely to augment the oncology drugs market growth over the forecast peri¬od. With over a decade of experience in the oncology space, Indivumed Group is making great strides in cancer treatment through individualized therapy. Indivumed GmbH was founded in 2002 by leading scientists with a drive to revolutionize cancer treat¬ment through individualized therapy.

As a physician-led, integrated global oncology company, experts at Indivumed leverage the world’s premier multi-omics oncology database and highest quality bio-bank to develop a true picture of cancer. The company’s three divisions operate holistically with one another for the generation, characterization, and analysis of biologic samples from human cancer patients. Indivumed is headquartered in Hamburg, Germany, with a US-based subsidiary and a global clinical network. Indivumed’s network enables the company to collect and analyse thousands of patient samples using a standardised approach to ensure biospecimen quality across three business units, namely IndivuServ, IndivuTest, and IndivuType. The unparalleled depth and quality of its data—coupled with the firm’s robust product and service offerings—gives them the ability to obtain novel insights and accelerate cancer research.

Soon after the company was founded in 2003, Indivumed Group was awarded as the ‘Best New Company’ in Hamburg, Germany. 22 years later, Indivumed was named ‘Germany’s Best Company’ in the visionary category, winning the German Foundation Award.

Since its founding, Indivumed has grown exponentially, its reputation for product and service quality and relationships expanding across the globe. The firm is always looking to the horizon for new partnerships and methods to support the realization of its vision. In 2011, IndivuTest GmbH was founded as a wholly-owned subsidiary of Indivumed to provide individualised diagnostics to oncologists and cancer patients to help select the most beneficial therapy. Further, in 2020 Indivumed launched a groundbreaking AI platform to leverage multi-omics data for discoveries in oncology.

Indivumed has established close and long-standing partnerships with leading hospitals, clinics, and biopharma institutes in Europe, North America, and Asia. The collaboration with these institutions is the basis for maintaining and expanding Indivumed’s high-quality biospecimens, clinical data, and breakthrough research techniques. Indivumed is continually expanding its clinical network in order to provide even better products and services for oncological drug discovery and development programs.

Indivumed’s goal is to illuminate biological correlates in cancer, thereby supporting the precision oncology of the future today. To ensure this level of quality, the firm applies over 100 standard operating procedures to the collection and curation of its wide variety of biospecimens and corresponding clinical data—worldwide. The standard operating procedures (SOP) have been developed through decades of experience, working side-by-side with surgeons and pathologists in the company’s global clinical network.

Indivumed, by integrating unique resources, partnerships, and decades of experience, has developed a comprehensive understanding of cancer. This allows the enterprise to act as a trusted service provider or see eye-to-eye as a development partner for precision oncology. For the road ahead, Indivumed will continue to unveil the complex mechanisms of cancer and advance precision oncology, combining the world’s most comprehensive multi-omics data with extensive medical experience, bioinformatics expertise, and AI-integrated advanced analytics.